Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To evaluate the efficacy of sarilumab at Week 16 in participants with non-infectious uveitis
(NIU).
Secondary Objectives:
To evaluate the change in best corrected visual acuity (BCVA). To evaluate the safety of
subcutaneous sarilumab in participants with NIU. To evaluate the change in macular edema. To
evaluate the change in other signs of ocular inflammation. To evaluate the effect on retinal
vessel leakage. To evaluate the effect of sarilumab on reducing concomitant immunosuppressant
therapy.
To evaluate the change in ocular inflammation in the anterior chamber. To evaluate the
pharmacokinetics of sarilumab in NIU participants. To evaluate the immunogenicity with
anti-drug antibodies (ADA).